Long-term efficacy of combination therapy with interferon-α2b and ribavirin for severe chronic hepatitis C in HIV-infected patients

AIDS

Volumn 15, Issue 16, 2001, Pages 2149-2155

  Landau, Alain ^a   Batisse, Dominique ^a   Piketty, Christophe ^a   Duong Van Huyen, Jean Paul ^a   Bloch, Francis ^a   Belec, Laurent ^a   Bruneval, Patrick ^a   Weiss, Laurence ^a   Jian, Raymond ^a   Kazatchkine, Michel D ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Hepatitis C; HIV; Interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; COUGHING; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENZYME ANALYSIS; FEMALE; GENOTYPE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRRITABILITY; LIVER CIRRHOSIS; LIVER DISEASE; LONG TERM CARE; LUNG ADENOCARCINOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; SCORING SYSTEM; SERODIAGNOSIS; VARICOSIS; VIRUS DETECTION;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 0035834534     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200111090-00010     Document Type: Article

References (32)

1. Hepatitis C virus infection in patients infected with the human immunodeficiency virus
2. Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus
3. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value
4. Mortality from liver cancer and liver disease in hemophilic men and boys in UK given blood products contaminated with hepatitis C
5. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
6. A controlled trial of two nucleosid analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
7. Liver fibrosis progression in human immunodeficiency virus and hepatitis C viruss coinfected patients
8. The progression of HCV-associated liver disease in a cohort of haemophiliacs patients
9. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy
10. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
11. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human infected immunodeficiency virus
12. Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study
13. Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C
14. Efficacy and safety of combination therapy with interferon-alpha 2b and ribavirin for chronic hepatitis c in HIV-infected patients
15. Randomised, double blind, placebo-controlled trial of interferon a-2b with and without ribavirin for chronic hepatitis C
16. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
17. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
18. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferona2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
19. Is an "à la carte" combination interferon alpha-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C
20. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
21. An algorithm for the grading of activity in chronic hepatitis C
22. Hepatitis C
23. Natural history of liver fibrosis progression in patients with chronic hepatitis C
24. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can sucessfully be retreated with consensus interferon
25. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: An early report
26. Relationship between hepatitis C virus genotypes and source of infection in patients with chronic hepatitis C
27. Increasing hepatitis C virus RNA levels in haemophiliacs; relationship to human immunodeficiency virus infection and liver disease
28. High hepatitis viremia and impaired antibody response in patients coinfected with HIV
29. Early predictors of response to treatment in patients with chronic hepatitis C
30. Severe hepatitis in three AIDS patients treated with indinavir
31. Changes in bone marrow of cancer patients treated with recombinant interferon alpha-2b
32. Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis